α2 アドレナゲン受容体の活性化によって引き起こされる腫瘍の免疫拒絶
Jingjing Zhu1,2,3, Stefan Naulaerts4,5, Loubna Boudhan4,5,6
1Ludwig Institute for Cancer Research, Brussels, Belgium. jingjng.zhu@uclouvain.be.
Nature
|June 7, 2023
まとめ
アルファ2アドレナゲン受容体 (α2-AR) のアゴニストは,免疫チェックポイントの阻害に抵抗するがんでも,単独療法として強力な抗腫瘍活性を示しています. これらの発見はα2-ARアゴニストががん免疫療法の有効性を高める可能性があることを示唆しています.
科学分野:
- 免疫学
- 薬理学について
- 腫瘍学
背景:
- 免疫チェックポイントブロック (ICB) 治療はがん治療において有望ですが,抵抗に直面しています.
- 免疫抑制剤とICBの組み合わせは,有効性が限られている.
- 腫瘍の微小環境の調節は,がんの免疫療法反応を改善するために不可欠です.
研究 の 目的:
- アルファ2- アドレナゲン受容体 (α2- AR) アゴニストの抗腫瘍能力を調査する.
- 癌におけるα2-ARアゴニストの作用機構と細胞標的を決定する.
- ICB耐性および免疫能力のあるがんモデルにおけるα2-ARアゴニストの有効性を評価する.
主な方法:
- α2-ARアゴニストを免疫能力と免疫欠乏性のマウス腫瘍モデルで単体療法として試験する.
- ヒトのリンパ球をヒトの腫瘍に移植する
- α2-ARアンタゴニストとAdra2aノックアウトマウスを用いて標的効果を確認する.
- 単細胞RNA配列と免疫細胞分析 (Tリンパ球,骨髄抑制細胞,マクロファージ) を行う.
主要な成果:
- α2- ARアゴニストは,ICB耐性を含む免疫能力のあるモデルでは有意な抗腫瘍活性を示したが,免疫欠陥のあるモデルではそうではなかった.
- 治療によりTリンパ球の浸透が増加し,アポプトシス・ミエロイド抑制細胞が減少した.
- 単細胞RNA配列解析により,マクロファージとT細胞の先天性および適応性免疫反応が強化されたことが明らかになった.
- α2- ARアゴニストには,CD4+,CD8+Tリンパ球とマクロファージが必要で,マクロファージに直接作用してTリンパ球を刺激する.
結論:
- α2- ARアゴニストは,宿主免疫細胞,特にマクロファージに作用する強力な固有の抗腫瘍活性を持っています.
- これらのアゴニストはICB抵抗を克服し,抗腫瘍免疫を強化します.
- 臨床的に利用可能なα2-ARアゴニストは,がん免疫療法の成果を改善するための有望な治療戦略です.
関連する概念動画
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Cell-mediated Immune Responses
83.5K
Overview
83.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Sympathetic Signaling
2.2K
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
2.2K


